Logo image
Crossover trial of gabapentin and memantine as treatment for acquired nystagmus
Journal article   Open access   Peer reviewed

Crossover trial of gabapentin and memantine as treatment for acquired nystagmus

Matthew J Thurtell, Anand C Joshi, Alice C Leone, Robert L Tomsak, Gregory S Kosmorsky, John S Stahl and R John Leigh
Annals of neurology, Vol.67(5), pp.676-680
05/2010
DOI: 10.1002/ana.21991
PMCID: PMC3064518
PMID: 20437565
url
https://www.ncbi.nlm.nih.gov/pmc/articles/3064518View
Open Access

Abstract

We conducted a masked, crossover, therapeutic trial of gabapentin (1,200mg/day) versus memantine (40 mg/day) for acquired nystagmus in 10 patients (aged 28-61 years; 7 female; 3 multiple sclerosis [MS]; 6 post-stroke; 1 post-traumatic). Nystagmus was pendular in 6 patients (4 oculopalatal tremor; 2 MS) and jerk upbeat, hemi-seesaw, torsional, or upbeat-diagonal in each of the others. For the group, both drugs reduced median eye speed (p < 0.001), gabapentin by 32.8% and memantine by 27.8%, and improved visual acuity (p < 0.05). Each patient improved with 1 or both drugs. Side effects included unsteadiness with gabapentin and lethargy with memantine. Both drugs should be considered as treatment for acquired forms of nystagmus.
Cyclohexanecarboxylic Acids - therapeutic use Excitatory Amino Acid Antagonists - therapeutic use Humans Middle Aged Male Eye Movements - drug effects Cross-Over Studies Amines - therapeutic use Adult Female gamma-Aminobutyric Acid - therapeutic use Memantine - therapeutic use Nystagmus, Pathologic - drug therapy

Details

Metrics

Logo image